Switching from originator to biosimilar infliximab (Remsima) in patients with inflammatory bowel disease (IBD)

Trial Profile

Switching from originator to biosimilar infliximab (Remsima) in patients with inflammatory bowel disease (IBD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Oct 2015 New trial record
    • 27 Oct 2015 Results presented at the United European Gastroenterology Week (UEG Week) 2015 in a satellite symposium, according to Celltrion media release.
    • 27 Oct 2015 Results published in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top